Maravai LifeSciences Holdings Inc
F:MAR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Maravai LifeSciences Holdings Inc
F:MAR
|
US |
|
D
|
Duke Energy Corp
DUS:D2MN
|
US |
|
Fujikura Ltd
F:FJK
|
JP |
|
A
|
Aflac Inc
XMUN:AFL
|
US |
|
M
|
Medifast Inc
SWB:MDF
|
US |
|
J
|
JD.Com Inc
SWB:013A
|
CN |
|
N
|
Newmont Corporation
DUS:NMM
|
US |
|
A
|
Atlas Copco AB
F:ACO2
|
SE |
|
F
|
Flowers Foods Inc
XBER:FWF
|
US |
|
S
|
Seven & i Holdings Co Ltd
DUS:S6M
|
JP |
|
Houston American Energy Corp
F:8H6H
|
US |
Maravai LifeSciences Holdings Inc
Maravai LifeSciences makes specialized reagents and tests that help other companies build and check DNA- and RNA-based medicines. Its main products include nucleic acid building blocks, mRNA-related chemistry, and protein-based tools used to detect impurities and measure quality in biologics manufacturing. The company sits upstream in the drug development process: it sells the materials and assays that researchers and manufacturers need before they can make a finished therapy or diagnostic. Its customers are mostly pharmaceutical and biotech companies, along with academic labs and other life sciences organizations. These buyers use Maravai’s products for research, drug development, vaccine work, and quality control. Maravai makes money mainly by selling consumable reagents and assay kits, so customers often come back whenever they start a new experiment or production run. What makes the business different is that it focuses on the narrow but important tools behind genetic medicines and biologics, not on the therapies themselves. That gives it a role as a supplier to many drug programs rather than a single end product maker. The company’s business depends on being a trusted source for precise, hard-to-make inputs that customers need to keep their research and manufacturing moving.
Maravai LifeSciences makes specialized reagents and tests that help other companies build and check DNA- and RNA-based medicines. Its main products include nucleic acid building blocks, mRNA-related chemistry, and protein-based tools used to detect impurities and measure quality in biologics manufacturing. The company sits upstream in the drug development process: it sells the materials and assays that researchers and manufacturers need before they can make a finished therapy or diagnostic.
Its customers are mostly pharmaceutical and biotech companies, along with academic labs and other life sciences organizations. These buyers use Maravai’s products for research, drug development, vaccine work, and quality control. Maravai makes money mainly by selling consumable reagents and assay kits, so customers often come back whenever they start a new experiment or production run.
What makes the business different is that it focuses on the narrow but important tools behind genetic medicines and biologics, not on the therapies themselves. That gives it a role as a supplier to many drug programs rather than a single end product maker. The company’s business depends on being a trusted source for precise, hard-to-make inputs that customers need to keep their research and manufacturing moving.
Revenue Beat: Full-year 2025 revenue was $185.7 million, exceeding guidance by about $700,000. Q4 revenue was $49.9 million.
Return to Profitability: The company delivered positive adjusted EBITDA of over $500,000 in Q4, its first positive quarter in a year, improving by about $11 million from Q3.
Cost Savings: Annualized cost reductions surpassed $65 million, exceeding the original $50 million target and driving significant margin improvements.
2026 Guidance: Maravai expects 2026 revenue between $200 million and $210 million (8% to 13% growth), with adjusted EBITDA of $18–20 million and gross margin expansion of 1,200 basis points.
Segment Performance: TriLink base revenue grew 25% YoY (excluding COVID CleanCap comp), and Cygnus revenue rose 4% in Q4. Both segments showed improved profitability.
Operational Improvements: Management highlighted greater customer engagement, operational automation, and a shift to a leaner, more responsive organization.
Strong Order Trends: Order volume and visibility have improved materially, especially in GMP consumables and larger discovery orders.
Product Innovation: New products like ModTail and IVT kits are gaining traction, with strong early adoption and positive customer feedback.
